Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6

[1]  L. Chao,et al.  Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. , 2013, Metabolism: clinical and experimental.

[2]  L. Chao,et al.  Kallistatin Inhibits Vascular Inflammation by Antagonizing Tumor Necrosis Factor-&agr;-Induced Nuclear Factor &kgr;B Activation , 2010, Hypertension.

[3]  L. Chao,et al.  Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway , 2010, Biological chemistry.

[4]  P. Chakraborty,et al.  The role of Wnt/beta-catenin signaling in renal carcinogenesis: lessons from cadmium toxicity studies. , 2010, Current molecular medicine.

[5]  L. Chao,et al.  Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin , 2010, BMC Cancer.

[6]  Ying Chen,et al.  Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family , 2010, Proceedings of the National Academy of Sciences.

[7]  G. Bu,et al.  LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy , 2010, Proceedings of the National Academy of Sciences.

[8]  L. Chao,et al.  Kruppel-like Factor 4 Is a Novel Mediator of Kallistatin in Inhibiting Endothelial Inflammation via Increased Endothelial Nitric-oxide Synthase Expression* , 2009, The Journal of Biological Chemistry.

[9]  Chika Yokota,et al.  Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions , 2007, Development.

[10]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[11]  T. Schlange,et al.  Novel c‐MYC target genes mediate differential effects on cell proliferation and migration , 2007, EMBO reports.

[12]  R. Nusse,et al.  Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors* , 2006, Journal of Biological Chemistry.

[13]  K. Arihiro,et al.  Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. , 2005, Oncology reports.

[14]  R. Widelitz.  Wnt signaling through canonical and non-canonical pathways: Recent progress , 2005, Growth factors.

[15]  L. Chao,et al.  Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. , 2005, Arthritis and rheumatism.

[16]  D. Brigstock,et al.  Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  E. Musgrove.  Wnt signalling via the epidermal growth factor receptor: a role in breast cancer? , 2003, Breast Cancer Research.

[18]  W. Robinson,et al.  Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. , 2003, Anticancer research.

[19]  H. Pitt,et al.  Vitamin A deficiency inhibits intestinal adaptation by modulating apoptosis, proliferation, and enterocyte migration. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[20]  Yoshiaki Kawano,et al.  Secreted antagonists of the Wnt signalling pathway , 2003, Journal of Cell Science.

[21]  Robert N. Taylor,et al.  beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. , 2003, Cancer research.

[22]  L. Chao,et al.  Structural elements of kallistatin required for inhibition of angiogenesis. , 2003, American journal of physiology. Cell physiology.

[23]  J. Behrens,et al.  The Wnt signaling pathway and its role in tumor development , 2003, Journal of Cancer Research and Clinical Oncology.

[24]  Lee Chao,et al.  Kallistatin is a new inhibitor of angiogenesis and tumor growth. , 2002, Blood.

[25]  D. Chung,et al.  Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. , 2001, Cancer research.

[26]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[27]  M. Benezra,et al.  A synthetic heparin‐mimicking polyanionic compound binds to the LDL receptor‐related protein and inhibits vascular smooth muscle cell proliferation , 2001, Journal of cellular biochemistry.

[28]  S. Jiang,et al.  Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  L. Chao,et al.  Identification of a Major Heparin-binding Site in Kallistatin* , 2001, The Journal of Biological Chemistry.

[30]  L. Chao,et al.  Roles of the P1, P2, and P3 Residues in Determining Inhibitory Specificity of Kallistatin toward Human Tissue Kallikrein* , 2000, The Journal of Biological Chemistry.

[31]  L. Chao,et al.  Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. , 2000, Biochimica et biophysica acta.

[32]  J. Behrens,et al.  Control of β‐Catenin Signaling in Tumor Development , 2000 .

[33]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[35]  L. Chao,et al.  Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. , 1996, The Journal of laboratory and clinical medicine.

[36]  C. Sherr,et al.  D-type cyclins. , 1995, Trends in biochemical sciences.

[37]  L. Chao,et al.  Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. , 1993, The Journal of biological chemistry.

[38]  J. Behrens,et al.  Control of beta-catenin signaling in tumor development. , 2000, Annals of the New York Academy of Sciences.

[39]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.